Breakthrough Therapies and Novel Approaches for Managing Patients with Treatment-Resistant Depression
The landscape for managing treatment-resistant depression (TRD)—a condition where patients do not respond to two or more conventional antidepressants—has been significantly altered by the introduction of rapid-acting and novel mechanism therapies. New options include esketamine nasal spray (SPRAVATO), which acts through glutamate pathways to provide rapid symptom relief, and intravenous ketamine therapy, which is particularly valuable for individuals needing immediate intervention due to the severity of their condition.